Anavex Life Sciences Corp (AVXL)

[nobrainerstocks]

Some people seem to have a hard time accepting statements from a small biotech company and doubt everything when it comes to scientific progress, no matter how many facts you throw at them.

The same goes for financing;

“We are entering the second half of 2017 with our strongest balance sheet to date, which allows the Company to execute the Phase 2 clinical trial in Rett syndrome, for which ANAVEX™ 2-73 has been granted Orphan Drug Designation by the FDA, as well as the Phase 2/3 clinical trial in Alzheimer’s disease and the Phase 2 clinical trial in Parkinson’s disease.”.

There are naysayers who believe that Anavex doesn't even have enough funding to bring the Alzheimer's trial to an end with the current cash at hand. Well, read again.

I'm not saying small biotechs haven't mislead investors in the past but Anavex looks pretty damn serious. As always, do your own due diligence and invest only what you can afford to lose.